M. Wittlinger

Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer

Arndt Hartmann, Rainer Fietkau, Michael Borre, 2012, BJU international.

Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment

B. Hadaschik, Christian Wagner, H. Christiansen, 2022, PloS one.

Time and dose-dependent activation of p53 serine 15 phosphorylation among cell lines with different radiation sensitivity

G. Grabenbauer, R. Sauer, L. Distel, 2007, International journal of radiation biology.

Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma

G. Grabenbauer, L. Distel, G. Niedobitek, 2009, BMC Cancer.

Treatment Options for High-Risk T1 Bladder Cancer

C. Rödel, R. Sauer, R. Fietkau, 2008, Strahlentherapie und Onkologie.

Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.

J. Dunst, C. Rödel, R. Sauer, 2008, International journal of radiation oncology, biology, physics.

Status Quo and Future Perspectives of Radiochemotherapy

C. Rödel, R. Sauer, R. Fietkau, 2008 .

Vogel Treatment Options for High-Risk T 1 Bladder Cancer Status Quo and Future Perspectives of Radiochemotherapy

C. Rödel, R. Sauer, R. Fietkau, 2008 .

Radiochemotherapy for bladder cancer.

C. Rödel, R. Sauer, R. Fietkau, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.

C. Rödel, F. Rödel, R. Sauer, 2009, International journal of radiation oncology, biology, physics.

Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.

Rainer Fietkau, Christian Weiss, C. Rödel, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Five years' results of the German ARO 04-01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer.

V. Budach, H. Iro, J. Werner, 2012 .